Reverse translation in tuberculosis: Neutrophils provide clues for understanding development of active disease

Frontiers in Immunology

Volumn 5, Issue FEB, 2014, Pages

  Dorhoi, Anca ^a   Iannaccone, Marco ^a   Maertzdorf, Jeroen ^a   Nouailles, Geraldine ^a   Weiner, January ^a   Kaufmann, Stefan H E ^a  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

Biomarker; Chemokine; Inflammation; Interferon; MicroRNA; Neutrophil; Tuberculosis

Indexed keywords

CD163 ANTIGEN; CD32 ANTIGEN; CD64 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CXCL14 CHEMOKINE; CXCL9 CHEMOKINE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FC RECEPTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; JANUS KINASE; MICRORNA 223; NEUTROPHIL COLLAGENASE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; TOLL LIKE RECEPTOR 5; TRANSCRIPTION FACTOR FOXC2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5; UNINDEXED DRUG;

CELL ACTIVATION; CELL MIGRATION; CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE COURSE; DRUG RESISTANT TUBERCULOSIS; GENE DELETION; GENE EXPRESSION; GRANULOPOIESIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SARCOIDOSIS; SIGNAL TRANSDUCTION; TUBERCULOSIS;

EID: 84895551138     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00036     Document Type: Review

References (89)

1. Kell DB, Oliver SG. Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays (2004) 26:99-105. doi:10.1002/bies.10385.
2. Maertzdorf J, Weiner J III, Kaufmann SH. Enabling biomarkers for tuberculosis control. Int J Tuberc Lung Dis (2012) 16:1140-8. doi:10.5588/ijtld.12.0246.
3. Weiner J, Maertzdorf J, Kaufmann SH. The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis. Ann N Y Acad Sci (2013) 1283:22-9. doi:10.1111/j.1749-6632.2012.06802.x.
4. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature (2008) 452:564-70. doi:10.1038/nature06915.
5. O'Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annu Rev Immunol (2013) 31:475-527. doi:10.1146/annurev-immunol-032712-095939.
6. WHO. Global Tuberculosis Report 2013. Geneva: WHO Press (2013).
7. UNAIDS; WHO. Global Report: UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: WHO (2013).
8. Collins HL, Kaufmann SHE. Prospects for better tuberculosis vaccines. Lancet Infect Dis (2001) 1:21-8. doi:10.1016/S1473-3099(01)00018-4.
9. Gengenbacher M, Kaufmann SHE. Mycobacterium tuberculosis: success through dormancy. FEMS Microbiol Rev (2012) 36:514-32. doi:10.1111/j.1574-6976.2012.00331.x.
10. Reece ST, Kaufmann SH. Floating between the poles of pathology and protection: can we pin down the granuloma in tuberculosis? Curr Opin Microbiol (2012) 15:63-70. doi:10.1016/j.mib.2011.10.006.
11. Russell DG, Barry CE III, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science (2010) 328:852-6. doi:10.1126/science.1184784.
12. Kaufmann SHE, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet (2010) 375:85-94. doi:10.1016/S0140-6736(10)60393-5.
13. Kaufmann SH. Tuberculosis vaccine development: strength lies in tenacity. Trends Immunol (2012) 33:373-9. doi:10.1016/j.it.2012.03.004.
14. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet (2010) 375:2100-9. doi:10.1016/S0140-6736(10)60359-9.
15. Lonnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, Glaziou P, et al. Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet (2010) 375:1814-29. doi:10.1016/S0140-6736(10)60483-7.
16. Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, et al. Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action. Lancet (2010) 375:2179-91. doi:10.1016/S0140-6736(10)60554-5.
17. Diel R, Vandeputte J, de Vries G, Stillo J, Wanlin M, Nienhaus A. Costs of tuberculosis disease in the EU-a systematic analysis and cost calculation. Eur Respir J (2014) 43:554-65. doi:10.1183/09031936.00079413.
18. Pulendran B, Li S, Nakaya HI. Systems vaccinology. Immunity (2010) 33:516-29. doi:10.1016/j.immuni.2010.10.006.
19. Diercks A, Aderem A. Systems approaches to dissecting immunity. Curr Top Microbiol Immunol (2013) 363:1-19. doi:10.1007/82_2012_246.
20. Mooney M, McWeeney S, Sekaly RP. Systems immunogenetics of vaccines. Semin Immunol (2013) 25:124-9. doi:10.1016/j.smim.2013.06.003.
21. Weiner J, Parida SK, Maertzdorf J, Black GF, Repsilber D, Telaar A, et al. Biomarkers of inflammation, immunosuppression and stress with active disease are revealed by metabolomic profiling of tuberculosis patients. PLoS One (2012) 7:e40221. doi:10.1371/journal.pone.0040221.
22. Sawyers CL. The cancer biomarker problem. Nature (2008) 452:548-52. doi:10.1038/nature06913.
23. Berry MP, Graham CM, McNab FW, Xu Z, Bloch SA, Oni T, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature (2010) 466:973-7. doi:10.1038/nature09247.
24. Maertzdorf J, Ota M, Repsilber D, Mollenkopf HJ, Weiner J, Hill PC, et al. Functional correlations of pathogenesis-driven gene expression signatures in tuberculosis. PLoS One (2011) 6:e26938. doi:10.1371/journal.pone.0026938.
25. Maertzdorf J, Repsilber D, Parida SK, Stanley K, Roberts T, Black G, et al. Human gene expression profiles of susceptibility and resistance in tuberculosis. Genes Immun (2011) 12:15-22. doi:10.1038/gene.2010.51.
26. Maertzdorf J, Weiner J III, Mollenkopf HJ, Bauer T, Prasse A, Muller-Quernheim J, et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci U S A (2012) 109:7853-8. doi:10.1073/pnas.1121072109.
27. Jacobsen M, Repsilber D, Kleinsteuber K, Gutschmidt A, Schommer-Leitner S, Black G, et al. Suppressor of cytokine signaling-3 is affected in T-cells from tuberculosis TB patients. Clin Microbiol Infect (2011) 17:1323-31. doi:10.1111/j.1469-0691.2010.03326.x.
28. Mistry R, Cliff JM, Clayton CL, Beyers N, Mohamed YS, Wilson PA, et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. J Infect Dis (2007) 195:357-65. doi:10.1086/510397.
29. Jacobsen M, Repsilber D, Gutschmidt A, Neher A, Feldmann K, Mollenkopf HJ, et al. Candidate biomarkers for discrimination between infection and disease caused by Mycobacterium tuberculosis. J Mol Med (Berl) (2007) 85:613-21. doi:10.1007/s00109-007-0157-6.
30. Lesho E, Forestiero FJ, Hirata MH, Hirata RD, Cecon L, Melo FF, et al. Transcriptional responses of host peripheral blood cells to tuberculosis infection. Tuberculosis (Edinb) (2011) 91:390-9. doi:10.1016/j.tube.2011.07.002.
31. Joosten SA, Goeman JJ, Sutherland JS, Opmeer L, de Boer KG, Jacobsen M, et al. Identification of biomarkers for tuberculosis disease using a novel dual-color RT-MLPA assay. Genes Immun (2012) 13:71-82. doi:10.1038/gene.2011.64.
32. Bloom CI, Graham CM, Berry MP, Rozakeas F, Redford PS, Wang Y, et al. Transcriptional blood signatures distinguish pulmonary tuberculosis, pulmonary sarcoidosis, pneumonias and lung cancers. PLoS One (2013) 8:e70630. doi:10.1371/journal.pone.0070630.
33. Koth LL, Solberg OD, Peng JC, Bhakta NR, Nguyen CP, Woodruff PG. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med (2011) 184:1153-63. doi:10.1164/rccm.201106-1143OC.
34. Kaforou M, Wright VJ, Oni T, French N, Andersen ST, Bangani N, et al. Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a case-control study. PLoS Med (2013) 10:e1001538. doi:10.1371/journal.pmed.1001538.
35. Zhang SY, Boisson-Dupuis S, Chapgier A, Yang K, Bustamante J, Puel A, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev (2008) 226:29-40. doi:10.1111/j.1600-065X.2008.00698.x.
36. Fortin A, Abel L, Casanova JL, Gros P. Host genetics of mycobacterial diseases in mice and men: forward genetic studies of BCG-osis and tuberculosis. Annu Rev Genomics Hum Genet (2007) 8:163-92. doi:10.1146/annurev.genom.8.080706.092315.
37. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol (2012) 12:125-35. doi:10.1038/nri3133.
38. Desvignes L, Wolf AJ, Ernst JD. Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol (2012) 188:6205-15. doi:10.4049/jimmunol.1200255.
39. Antonelli LR, Gigliotti RA, Goncalves R, Roffe E, Cheever AW, Bafica A, et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J Clin Invest (2010) 120:1674-82. doi:10.1172/JCI40817.
40. Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, et al. Mycobacterium tuberculosis triggers host type I IFN signaling to regulate IL-1beta production in human macrophages. J Immunol (2011) 187:2540-7. doi:10.4049/jimmunol.1100926.
41. Mayer-Barber KD, Andrade BB, Barber DL, Hieny S, Feng CG, Caspar P, et al. Innate and adaptive interferons suppress IL-1alpha and IL-1beta production by distinct pulmonary myeloid subsets during Mycobacterium tuberculosis infection. Immunity (2011) 35:1023-34. doi:10.1016/j.immuni.2011.12.002.
42. Trinchieri G. Type I interferon: friend or foe? J Exp Med (2010) 207:2053-63. doi:10.1084/jem.20101664.
43. Majer O, Bourgeois C, Zwolanek F, Lassnig C, Kerjaschki D, Mack M, et al. Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections. PLoS Pathog (2012) 8:e1002811. doi:10.1371/journal.ppat.1002811.
44. Lee PY, Li Y, Kumagai Y, Xu Y, Weinstein JS, Kellner ES, et al. Type I interferon modulates monocyte recruitment and maturation in chronic inflammation. Am J Pathol (2009) 175:2023-33. doi:10.2353/ajpath.2009.090328.
45. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science (2013) 340:207-11. doi:10.1126/science.1235214.
46. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science (2013) 340:202-7. doi:10.1126/science.1235208.
47. Teles RM, Graeber TG, Krutzik SR, Montoya D, Schenk M, Lee DJ, et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science (2013) 339:1448-53. doi:10.1126/science.1233665.
48. Bogunovic D, Byun M, Durfee LA, Abhyankar A, Sanal O, Mansouri D, et al. Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency. Science (2012) 337:1684-8. doi:10.1126/science.1224026.
49. Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis (2013) 13:362-72. doi:10.1016/S1473-3099(13)70034-3.
50. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 11:597-610. doi:10.1038/nrg2843.
51. Fu Y, Yi Z, Wu X, Li J, Xu F. Circulating microRNAs in patients with active pulmonary tuberculosis. J Clin Microbiol (2011) 49:4246-51. doi:10.1128/JCM.05459-11.
52. Kleinsteuber K, Heesch K, Schattling S, Kohns M, Sander-Julch C, Walzl G, et al. Decreased expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4(+) T cells and peripheral blood from tuberculosis patients. PLoS One (2013) 8:e61609. doi:10.1371/journal.pone.0061609.
53. Qi Y, Cui L, Ge Y, Shi Z, Zhao K, Guo X, et al. Altered serum microRNAs as biomarkers for the early diagnosis of pulmonary tuberculosis infection. BMC Infect Dis (2012) 12:384. doi:10.1186/1471-2334-12-384.
54. Wang C, Yang S, Sun G, Tang X, Lu S, Neyrolles O, et al. Comparative miRNA expression profiles in individuals with latent and active tuberculosis. PLoS One (2011) 6:e25832. doi:10.1371/journal.pone.0025832.
55. Yi Z, Fu Y, Ji R, Li R, Guan Z. Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis. PLoS One (2012) 7:e43184. doi:10.1371/journal.pone.0043184.
56. Dorhoi A, Iannaccone M, Farinacci M, Fae KC, Schreiber J, Moura-Alves P, et al. MicroRNA-223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J Clin Invest (2013) 123(11):4836-48. doi:10.1172/JCI67604.
57. Liu Y, Jiang J, Wang X, Zhai F, Cheng X. miR-582-5p is upregulated in patients with active tuberculosis and inhibits apoptosis of monocytes by targeting FOXO1. PLoS One (2013) 8:e78381. doi:10.1371/journal.pone.0078381.
58. Spinelli SV, Diaz A, D'Attilio L, Marchesini MM, Bogue C, Bay ML, et al. Altered microRNA expression levels in mononuclear cells of patients with pulmonary and pleural tuberculosis and their relation with components of the immune response. Mol Immunol (2013) 53:265-9. doi:10.1016/j.molimm.2012.08.008.
59. Wu J, Lu C, Diao N, Zhang S, Wang S, Wang F, et al. Analysis of microRNA expression profiling identifies miR-155 and miR-155* as potential diagnostic markers for active tuberculosis: a preliminary study. Hum Immunol (2012) 73:31-7. doi:10.1016/j.humimm.2011.10.003.
60. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature (2008) 451:1125-9. doi:10.1038/nature06607.
61. Fazi F, Rosa A, Fatica A, Gelmetti V, De Marchis ML, Nervi C, et al. A minicircuitry comprised of microRNA-223 and transcription factors NFI-A and C/EBPalpha regulates human granulopoiesis. Cell (2005) 123:819-31. doi:10.1016/j.cell.2005.09.023.
62. Fukao T, Fukuda Y, Kiga K, Sharif J, Hino K, Enomoto Y, et al. An evolutionarily conserved mechanism for microRNA-223 expression revealed by microRNA gene profiling. Cell (2007) 129:617-31. doi:10.1016/j.cell.2007.02.048.
63. Haneklaus M, Gerlic M, Kurowska-Stolarska M, Rainey AA, Pich D, McInnes IB, et al. Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1beta production. J Immunol (2012) 189:3795-9. doi:10.4049/jimmunol.1200312.
64. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat Immunol (2010) 11:799-805. doi:10.1038/ni.1918.
65. Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. Identification and characterization of macrophage inflammatory protein 2. Proc Natl Acad Sci U S A (1989) 86:612-6. doi:10.1073/pnas.86.2.612.
66. Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med (1988) 167:570-81. doi:10.1084/jem.167.2.570.
67. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte colony-stimulating factor receptor are major independent regulators of granulopoiesis in vivo but are not required for lineage commitment or terminal differentiation. Blood (1997) 90:2583-90.
68. Eruslanov EB, Lyadova IV, Kondratieva TK, Majorov KB, Scheglov IV, Orlova MO, et al. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect Immun (2005) 73:1744-53. doi:10.1128/IAI.73.3.1744-1753.2005.
69. Keller C, Hoffmann R, Lang R, Brandau S, Hermann C, Ehlers S. Genetically determined susceptibility to tuberculosis in mice causally involves accelerated and enhanced recruitment of granulocytes. Infect Immun (2006) 74:4295-309. doi:10.1128/IAI.00057-06.
70. Marzo E, Vilaplana C, Tapia G, Diaz J, Garcia V, Cardona PJ. Damaging role of neutrophilic infiltration in a mouse model of progressive tuberculosis. Tuberculosis (Edinb) (2014) 94:55-64. doi:10.1016/j.tube.2013.09.004.
71. Vilaplana C, Marzo E, Tapia G, Diaz J, Garcia V, Cardona PJ. Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis. J Infect Dis (2013) 208:199-202. doi:10.1093/infdis/jit152.
72. Dorhoi A, Desel C, Yeremeev V, Pradl L, Brinkmann V, Mollenkopf HJ, et al. The adaptor molecule CARD9 is essential for tuberculosis control. J Exp Med (2010) 207:777-92. doi:10.1084/jem.20090067.
73. Eum SY, Kong JH, Hong MS, Lee YJ, Kim JH, Hwang SH, et al. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest (2010) 137:122-8. doi:10.1378/chest.09-0903.
74. Lowe DM, Redford PS, Wilkinson RJ, O'Garra A, Martineau AR. Neutrophils in tuberculosis: friend or foe? Trends Immunol (2012) 33:14-25. doi:10.1016/j.it.2011.10.003.
75. Yang CT, Cambier CJ, Davis JM, Hall CJ, Crosier PS, Ramakrishnan L. Neutrophils exert protection in the early tuberculous granuloma by oxidative killing of mycobacteria phagocytosed from infected macrophages. Cell Host Microbe (2012) 12:301-12. doi:10.1016/j.chom.2012.07.009.
76. Blomgran R, Desvignes L, Briken V, Ernst JD. Mycobacterium tuberculosis inhibits neutrophil apoptosis, leading to delayed activation of naive CD4 T cells. Cell Host Microbe (2012) 11:81-90. doi:10.1016/j.chom.2011.11.012.
77. Blomgran R, Ernst JD. Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol (2011) 186:7110-9. doi:10.4049/jimmunol.1100001.
78. Slight SR, Khader SA. Chemokines shape the immune responses to tuberculosis. Cytokine Growth Factor Rev (2013) 24:105-13. doi:10.1016/j.cytogfr.2012.10.002.
79. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity (2012) 36:705-16. doi:10.1016/j.immuni.2012.05.008.
80. Bhatia M, Zemans RL, Jeyaseelan S. Role of chemokines in the pathogenesis of acute lung injury. Am J Respir Cell Mol Biol (2012) 46:566-72. doi:10.1165/rcmb.2011-0392TR.
81. Kang DD, Lin Y, Moreno JR, Randall TD, Khader SA. Profiling early lung immune responses in the mouse model of tuberculosis. PLoS One (2011) 6:e16161. doi:10.1371/journal.pone.0016161.
82. Goncalves AS, Appelberg R. The involvement of the chemokine receptor CXCR2 in neutrophil recruitment in LPS-induced inflammation and in Mycobacterium avium infection. Scand J Immunol (2002) 55:585-91. doi:10.1046/j.1365-3083.2002.01097.x.
83. Nouailles G, Dorhoi A, Koch M, Zerrahn J, Weiner J III, Fae KC, et al. CXCL5/LIX-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis. J Clin Invest (2013). doi:10.1172/JCI72030.
84. Cai S, Batra S, Lira SA, Kolls JK, Jeyaseelan S. CXCL1 regulates pulmonary host defense to Klebsiella infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. J Immunol (2010) 185:6214-25. doi:10.4049/jimmunol.0903843.
85. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, et al. Induction of CXCL5 during inflammation in the rodent lung involves activation of alveolar epithelium. Am J Respir Cell Mol Biol (2005) 32:531-9. doi:10.1165/rcmb.2005-0063OC.
86. Yamamoto K, Ferrari JD, Cao Y, Ramirez MI, Jones MR, Quinton LJ, et al. Type I alveolar epithelial cells mount innate immune responses during pneumococcal pneumonia. J Immunol (2012) 189:2450-9. doi:10.4049/jimmunol.1200634.
87. Madorin WS, Rui T, Sugimoto N, Handa O, Cepinskas G, Kvietys PR. Cardiac myocytes activated by septic plasma promote neutrophil transendothelial migration: role of platelet-activating factor and the chemokines LIX and KC. Circ Res (2004) 94:944-51. doi:10.1161/01.RES.0000124395.20249.AE.
88. Mei J, Liu Y, Dai N, Hoffmann C, Hudock KM, Zhang P, et al. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest (2012) 122:974-86. doi:10.1172/JCI60588.
89. Rousselle A, Qadri F, Leukel L, Yilmaz R, Fontaine JF, Sihn G, et al. CXCL5 limits macrophage foam cell formation in atherosclerosis. J Clin Invest (2013) 123:1343-7. doi:10.1172/JCI66580.